Author

Kuan-Ting Lin

Cold Spring Harbor LaboratoryORCID 0009-0007-4381-9947Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:GWAS / association mapping· 1 Assay:GWAS summary statistics· 1

Frequent Co-Authors

Adrian R. KraineriD· 1 shared Alexander J. KraliD· 1 shared Bu‐Yuan HsiaoiD· 1 shared Cathy S.-J. FanniD· 1 shared Chang‐Fu KuoiD· 1 shared Chao‐Wei LeeiD· 1 shared Chau‐Chyun SheuiD· 1 shared Chaur‐Jong HuiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrian R. KrainerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 7, 2026

The Spliceosome Scaffold Component BCAS2 Promotes Pancreatic Cancer Progression through Weak 5 Splice Site Dependent Splicing Regulation

Ledong Wan, Mei Wang, Yuma Ishigami…·Adrian R. Krainer

This study identifies BCAS2 as a critical regulator of PDAC progression by promoting alternative splicing of weak 5' splice sites, specifically enhancing SOS1 exon 21 inclusion and RAC-signaling activation.

DOI 10.64898/2026.10.06.757127

humanbulk RNA-seq

𝕏 PostBluesky

Genetic & Genomic MedicineNature CommunicationsPeer-reviewedJul 9, 2025

Clinical Impact of Pharmacogenetic Risk Variants in a Large Chinese Cohort

Chun-Yu Wei, Ming‐Shien Wen, Chih-Kuang Cheng…·Chien‐Ming Lin

The paper evaluates the clinical impact of pharmacogenetic risk variants in a large Han Chinese cohort, finding that while most carry risk variants, the excess risk of adverse events is small and most patients do not experience adverse outcomes.

15 citationstop 1%

humanGWAS summary statistics

𝕏 PostBluesky